Downward price trends and negative momentum for Regencell Bioscience Holdings (RGC) are primarily attributed to the high-risk, pre-revenue nature of clinical-stage biotechnology firms, combined with negative financial returns on equity and lack of traditional commercial revenue streams. Market analyses highlight that small-cap biopharmaceutical equities lacking steady commercial product sales experience extreme volatility, wide trading spreads, and heavy sensitivity to speculative sentiment. Furthermore, negative earnings reports, ongoing securities class-action legal scrutiny, and technical moving average indicators pointing toward bearish trends have contributed to sustained downward selling pressures among cautious market participants.